Echelon Wealth Partners Keeps Their Buy Rating on IMV (IMV)


In a report issued on August 12, Douglas Loe from Echelon Wealth Partners maintained a Buy rating on IMV (IMV), with a price target of C$10.50. The company’s shares closed last Monday at $4.21.

According to TipRanks.com, Loe is a 4-star analyst with an average return of 9.1% and a 50.0% success rate. Loe covers the Healthcare sector, focusing on stocks such as Neptune Wellness Solutions, IntelGenx Technologies, and Kalytera Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IMV with a $8.48 average price target, an 86.4% upside from current levels. In a report issued on August 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

Based on IMV’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $68K and GAAP net loss of $9.66 million. In comparison, last year the company earned revenue of $186K and had a GAAP net loss of $5.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm’s candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck’s Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

Read More on IMV:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts